CCPM and Others Urge Congress to Fix or Drop Biologics Provisions

According to this post on Reuters many organizations including the CCPM, several hundred many Americans, experts from the medical and researhc community, economists, and thought leaders have joined together appealing to Congress to fix the 12 year market exclusivity for biologics or drop it altogether.

There has been an on-going battle on this topic, and Annette Guarisco, CCPM Chairman mentions:

"Finding the right balance between incentives for innovation and timely access
to care means that Congress needs to fix or drop the current biogenerics provision. We call on Congress to take this opportunity to truly constrain costs to benefit all health care purchasers, and override the lobby of the big pharmaceutical and biotech companies."

Perhaps now that the The Coalition for a Competitive Pharmaceutical Market has joined the fight Congress will begin to listen.

If you're interested in networking with other professionals in the field of Biosimilars, join our LinkedIn Group here.

Share this article with your social network, just click below to share now!

Share |

Future Drug Sales Predictions Highlight Importance of Follow-on Biologics Legislation

According to Patent Docs, "six of the top ten selling drugs by 2014 will be biologics. Today, half of the top ten best-selling drugs are conventional small molecule drugs, as shown in the table below; in terms of sales, these drugs account for about 61% of the revenues garnered by the top ten best-selling drugs."

Check out the chart : Top 10 Drug Products by Sales in 2008

But by 2014, the number of drugs sold that are biologics "are predicted to account for a 75% of the revenues, an almost 2-fold increase in the relative contributions of biologic drugs to the sector."

Check out the chart: Top 10 Drug Products by Sales in 2014

According to the article, "some traditional Big Pharma companies stand to benefit from their association (partnering) or acquisition of biotechnology companies, with Roche being a clear example as purveyors of three of the top ten predicted best-selling drugs in 2014."

For more information, please click here.

Future Drug Sales Predictions Highlight Importance of Follow-on Biologics Legislation

Gather with other professionals to discuss the emerging trends in Pharma, including biopharma strategy, R&D, product marketing, clinical studies-- join Future of BioPharma, today!

Share this article with your social network, just click below to share now!

Share |